MedTrace Logo

Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure

NCT06140251 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2023-11-18

No results posted yet for this study

Summary

This is a 26-week, open label, single-arm prospective evaluation of the effects of sodium glucose cotransporter 2 (SGLT2) inhibition on cardiac biomarkers, myocardial remodeling and patient reported outcomes in heart failure with both impaired and preserved left ventricular fraction.

Conditions

Interventions

DRUG

Sodium-glucose cotransporter 2 inhibitor

Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.

Sponsors & Collaborators

  • Belfast Health and Social Care Trust

    collaborator OTHER

  • Queen's University, Belfast

    lead OTHER

Principal Investigators

  • Chris Watson, PHD · Queens University Belfast

  • Lana Dixon, MD · Belfast Health and Social Care Trust

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-21
Primary Completion
2024-09-01
Completion
2025-05-01
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06140251 on ClinicalTrials.gov